Synbio Launches Nutraceutical Product Line with AI-Enabled Mental Health Screenings

Synbio International, Inc., a healthcare company pursuing a dual-track strategy, has outlined a two-engine growth plan combining nutraceuticals and AI-powered mental health screening. The company has already launched its Healing Force™ nutraceutical division, with the first planned consumer product, Healing Force™ Anxiety Relief, set to be launched on August 11, 2026. This marks Synbio’s entry into commercial operations, with the Healing Force™ nutraceutical division controlling branding, marketing, sales, and distribution while its partner provides established product development, manufacturing, and supply-chain capability.

The company has also entered into a licensing, manufacturing, supply, and revenue-sharing agreement with MD PHD Wellness, Inc., giving Synbio exclusive commercialization rights. Under this agreement, Synbio will control the branding, marketing, sales, and distribution of the Healing Force™ nutraceutical products, while MD PHD Wellness will handle the development, manufacturing, and quality assurance of the products.

The company is also advancing the clinical validation of FacialDx Inc.’s NIMS™ (Non-invasive Medical Screening) facial-analysis platform as a potential screening aid for mental health conditions, including depression and post-traumatic stress disorder (PTSD). The NIMS™ platform uses AI analysis of facial imagery and visual biomarkers to identify features that may be associated with behavioral and mental health conditions. The next milestone for the FacialDx program is a focused feasibility study in Australia using retrospective clinical data, which is designed to provide a relatively short pathway to assessing whether NIMS™ delivers reliable, repeatable results.

Synbio has executed agreements with FacialDx and a subsidiary of ASX-listed Resonance Health Ltd., providing for a staged investment in FacialDx, with rights, subject to conditions, to convert certain clinical trial spending into additional FacialDx equity. The company has allocated funding towards its nutraceutical operations and is pursuing a clinical-program financing structure that, if completed as contemplated, would not further dilute existing shareholders.

The market for mental health conditions is massive and underserved, with the World Health Organization estimating that more than one billion people worldwide live with a mental health condition, and depression and anxiety alone cost the global economy an estimated US$1 trillion a year in lost productivity. Screening still relies largely on subjective questionnaires and self-reporting, and Synbio believes a rapid, non-invasive screening tool could find applications beyond the clinic, in safety-sensitive industries such as aviation and emergency services, where objective mental health screening is increasingly in demand.

Synbio International, Inc. is a healthcare company pursuing a dual-track strategy: commercializing consumer wellness products through its Healing Force™ nutraceutical division and advancing the clinical validation of FacialDx Inc.’s AI-powered NIMS™ facial-analysis platform as a potential screening aid for mental health conditions. The company has already launched its Healing Force™ nutraceutical division, with the first planned consumer product, Healing Force™ Anxiety Relief, set to be launched on August 11, 2026. This marks Synbio’s entry into commercial operations, with the Healing Force™ nutraceutical division controlling branding, marketing, sales, and distribution while its partner provides established product development, manufacturing, and supply-chain capability. The company is also advancing the clinical validation of FacialDx Inc.’s NIMS™ (Non-invasive Medical Screening) facial-analysis platform as a potential screening aid for mental health conditions, including depression and post-traumatic stress disorder (PTSD). The next milestone for the FacialDx program is a focused feasibility study in Australia using retrospective clinical data, which is designed to provide a relatively short pathway to assessing whether NIMS™ delivers reliable, repeatable results. Synbio has executed agreements with FacialDx and a subsidiary of ASX-listed Resonance Health Ltd., providing for a staged investment in FacialDx, with rights, subject to conditions, to convert certain clinical trial spending into additional FacialDx equity. The company has allocated funding towards its nutraceutical operations and is pursuing a clinical-program financing structure that, if completed as contemplated, would not further dilute existing shareholders. The market for mental health conditions is massive and underserved, with the World Health Organization estimating that more than one billion people worldwide live with a mental health condition, and depression and anxiety alone cost the global economy an estimated US$1 trillion a year in lost productivity. Screening still relies largely on subjective questionnaires and self-reporting, and Synbio believes a rapid, non-invasive screening tool could find applications beyond the clinic, in safety-sensitive industries such as aviation and emergency services, where objective mental health screening is increasingly in demand.